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The phase III HIV-1 trial RV144 in Thailand tested the efficacy of a vaccine consisting in priming 
with a canarypox vector carrying three HIV genes (gag, pol and env) and boosting wth the protein 
gp120 env. The tested vaccine has so far been the only one showing protection from HIV-1 infection, 
although with a limited efficacy of 31.2% efficacy. Post hoc analyses of the trial results showed that 
HIV-specific Immunoglobulin (Ig) G binding to the envelope (Env) V1V2 region inversely correlated 
with infection risk, while the presence of IgA directly correlated with the risk of infection. 
This finding led to the hypothesis that IgG protection is not related to their capacity to bind and 
neutralize the virus, but to their fragment crystallizable (Fc)-mediated function. Antibodies can have 
functions such as antibody-dependent cellular cytotoxicity, requiring the recognition of Fc by specific 
receptors (FcR) on effector cells, which can be inhibited by the presence of IgA, recognized by the 
same FcR. 
Prompted by this major finding in HIV research, Drs. Shuying Li and Peter Gilbert from the Vaccine 
and Infectious Disease Division (VIDD) and their collaborators investigated the correlation between 
genetic polymorphisms in the FcR-encoding sequences and surrounding areas and vaccine 
protection.  Their results were published in The Journal of Clinical Investigation. 
The authors evaluated single nucleotide polymorphisms (SNPs) in six different human FcR genes 
(FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B, and FCAR) and found that the SNP 
rs114943036 in FCGR2C was significantly associated with vaccine efficacy. The vaccine was 
effective against a particular genotype of HIV-1 in 91% of individuals carrying CT or TT genotypes 
compared with 15% of individuals carrying the CC genotype. Furthermore, they found Env-specific 
IgG and subclass IgG3 antibodies (Abs), IgG avidity, and neutralizing Abs inversely correlated with 
the infection risk but only in the vaccine recipients who carried the CT or TT genotype. 
These results open new questions regarding the functional significance of this polymorphism, in 
particular on its effects on FcR structure, function or expression. To this regard, Dr. Sue Li of the 
Statistical Center for HIV/AIDS Prevention, comments: "Our paper is the first report of an association 
between FCGR2C 126C>T and prevention efficacy against any clinical outcomes.  FCGR2C is a  
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product of unequal crossover between FCGR2A and FCGR2B. This gene structure is complex and 
is not well studied in the literature. The functional significance and implication of this association 
remains to be established. Dr. Daniel Geraghty from the Clinical Research Division is applying for 
funding to pursue experimental approaches to study the function of the polymorphisms and to 
distinguish whether the genetic variants detected in this study were themselves causal or in linkage 
with other causal variations that were not genotyped in this study." 
  
When asked about the significance of this study for HIV research, Dr. Li adds: "Our data suggest a 
potent role of Fc-γ receptors and Fc-mediated Ab function in conferring protection from transmission 
risk in the RV144 trial. We hope that new immune correlates of risk identified in host genetic 
subgroups in this study will inform/direct future experiments and vaccine trials that can increase 
knowledge about mechanisms of vaccine protections. Understanding the process of Ab-mediated 
vaccine protection, where virus neutralization and Fc-FcR interaction together achieve immune 
protection, is critical for HIV vaccine design.”  Furthermore, ”our study demonstrates the importance 
of considering host immune genetics in assessments of vaccine efficacy, immune correlates of risk, 
and sieve analysis of viral sequences data." 
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Image provided by Dr. Shuying Li 
Association of FCGR2C 126C>T (rs114945036) genotype with 
vaccine efficacy (VE) against any HIV-1 strains (VE=11% among 
individuals carrying CC genotype vs. 64% among individuals 
carrying CT or TT genotype, p-value=0.04) and VE against HIV-
1 subtype CRF01_AE with lysine at position 169 (169K) in the 
V2 loop (VE=15% among individuals carrying CC genotype vs. 
64% among individuals carrying CT or TT genotype, p-
value=0.004 and 0.05 after multiplicity correction for 28 tag 
SNPs). The error bars are 95% confidence intervals for the 
estimated VEs. The numbers on the bottom of each plot are the 
numbers of infected individuals by vaccine arm (vaccine vs. 
placebo) and FCGR2C 126C>T genotype group (CC vs. CT or 
TT). Case-only statistical method (Dai, Li, and Gilbert, 2014) was 
used to estimate and test the difference of VE between the host 
genotype groups. 
 
